Member Info for BuenaVista

Thanks Thompi. I thought it might be a paid service.

My concern was whether it is ethical to provide such potentially market-sensitive information on a subscription service rather than to the whole market.

No, it's just 'doing coffee'

How can one access PL's broker note?

Just remember: you can't educate a troll.

It's all a white water ride with Avacta.

I just pull you out of the bin to have a laugh.

Good point. I forgot about that in my comments about that PL interview. Tbh, I didn't understand wtf she was on about.

Receieved and actioned.

Memo to self: put Pharma3 back in the bin.

Correctly formatted Google links:

Fibroblast activation protein in disease: https://www.google.com/search?q=%27fibroblast+activation+protein%27+in+disease

Pathway inhibitors in...

- Cancer: https://www.google.com/search?q=%27pathway+inhibitors%27+in+cancer

- Fibrosis: https://www.google.com/search?q=%27pathway+inhibitors%27+in+fibrosis

- Wound healing: https://www.google.com/search?q=%27pathway+inhibitors%27+in+wound+healing

- Inflammation: https://www.google.com/search?q=%27pathway+inhibitors%27+in+inflammation

- Arthritis: https://www.google.com/search?q=%27pathway+inhibitors%27+in+arthritis

- Atherosclerosis: https://www.google.com/search?q=%27pathway+inhibitors%27+in+atherosclerosis

Pathway inhibitor...

- Side-effects: https://www.google.com/search?q=%27pathway+inhibitor%27+side-effects

- Toxicity: https://www.google.com/search?q=%27pathway+inhibitor%27+toxicity

Something in the Panmure Liberum interview that has so far gone unnoticed was a little mention CC slipped in @ 15:10, transcript below:

Interviewer: The pre|CISION technology has clearly got very broad application. Can you expand on the other potential uses it has?

CC: So, one of the next medicines that we're looking to make is a targeted therapy, so it's not just chemotherapy. I know the first two have been sort of traditional chemotherapies but pathway inhibitors for example have been very effective in a number of diseases but they also can carry some very high toxicities and so therapeutic index with pathway inhibitors is also a problem. We hope to see one of those coming soon to the clinic. [CC then uses mouse and mobile to start talking about AVA7100]

https://fast.wistia.net/embed/iframe/jhkzsr4536

'Pathway inhibitors' is a ubiquitous term meaning inhibitors of biochemical/cellular pathways. Doxorubicin (topoisomerase II inhibitor) and exatecan (topoisomerase I inhibitor) are both pathway inhibitors, as is bortezomib (proteasome inhibitor). Bachovchin's team couldn't link bortezomib itself to the pre|CISION dipeptide because the chemistry didn't work, so they developed an analog, a chemically similar version, that they could link, which Avacta called AVA3996. With their new chemistry techniques Avacta can now probably make a bortezomib prodrug using pre|CISION should they so wish. The bortezomib patents in the US expired in 2022 and the drug is tumour agnostic so has very wide application.

It would be very ambitious for Avacta at this stage in their development to add another therapeutic area with all the inhouse expertise and scientific advisors that that would entail. Their strategy has been to take off-patent cytotoxins and target them to tumours so a pre|CISIONed bortezomib could be a definite possibility for a future oncology pipeline candidate.

However other companies could use pre|CISION with pathway inhibitors to treat indications in other therapeutic areas. Here are some links to Google searches about this that lead to a lot of information about what could be possible:

Fibroblast activation protein in disease: https://www.google.com/search?q=%27fibroblast+activation+protein%27+in+disease

Pathway inhibitors in...

- Cancer: https://www.google.com/search?q='pathway+inhibitors'+in+cancer

- Fibrosis: https://www.google.com/search?q='pathway+inhibitors'+in+fibrosis

- Wound healing: https://www.google.com/search?q='pathway+inhibitors'+in+wound+healing

- Inflammation: https://www.google.com/search?q='pathway+inhibitors'+in+inflammation

- Arthritis: https://www.google.com/search?q='pathway+inhibitors'+in+arthritis

- Atherosclerosis: https://www.google.com/search?q='pathway+inhibitors'+in+atherosclerosis

Pathway inhibitor...

- Side-effects: https://www.google.com/search?q='pathway+inhibitor'+side-effects

- Toxicity: https://www.google.com/search?q='pathway+inhibitor'+toxicity

All will be revealed...

Very good. Thank you thevid.

The troll asks "Why is significantly boosting the half life so exciting?"

It's clear the troll didn't watch yesterday's and the other recent presentations. Or if it did, it didn't understand.

Avacta only has the financial capacity to take AVA6000 to market for one indication at a time. That is now clearly SGC and the core reason is the lack of a SoC for SGC, so FDA support and AA are likely if Phase 1b are as expected.

As regards STS, I'd say partnership or licensing out is likely but, failing either of those, Avacta would develop AVA6000 for that indication once there was revenue available. However, I think a buyout would happen long before we got to that.

Probably because it would get to market around the time the patent life expired.

Just call them out as trolls so newbies get the message. That gives them nothing to argue against, they can only whine.

Opti_mystic, you haven't been here long and I don't know how long you've been using onlne forums, but you need to learn that it is worse than absolutely useless to engage with these trolls whose only purpose here is to stir up trouble. Why worse than absolutely useless? BECAUSE YOU ARE FEEDING THEM and giving them opportunity to come back with more misinformation and shyte. Do that for too long and you'll be filtered like Icecool and Watching are and the only ones taking any notice of your carefully crafted, rational and factual responses will be the trolls - looking for an angle to respond and wind you up. They do not care anything about the facts about Avacta. Thorn/NDN/Eggy is actually paid by Tom Winnifrith to troll Avacta - he was publicly outed a couple of years ago when in his NDN guise.

So Tom Winnifrith has primed his professorial poodle with presentation-related drivel already. Ignore.

This is new. Down at the bottom of slide 9, approximately mid-2025 to mid-2026 which is from the latter part of the TNBC Phase 1b trial (when the results are coming in) through to the early part of the TNBC Phase 2 trial.

https://wsw.com/webcast/leerink38/avctf/2396932 at 08:25